Saraton antigeni (CA) 15-3
Kod:10007|CPT:86300|LOINC:6875-9
| Kabi | Saraton antigeni 15-3 |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Elektrokimyoluminessent immunoanaliz (ECLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Do not smoke for at least 30 minutes before the blood draw.
- For longitudinal monitoring, use the same assay platform; avoid comparing results across different methods.
- Review for high-dose biotin (vitamin B7/B8, vitamin H, coenzyme R) intake and discontinue supplementation for a minimum of 72 hours before collection.
Qanday foydalanish
Saraton antigeni (CA) 15-3, shuningdek “cancer antigen 15-3” yoki “carbohydrate antigen 15-3” nomlari bilan ham ma’lum, ko‘krak bezi karsinomasida terapevtik javobni kuzatib borish va, ayniqsa bemorning boshlang‘ich CA 15-3 darajasi yuqori bo‘lganda, qaytalanishni nazorat qilish uchun qo‘llanadi. Natijalar klinik ko‘rik va tasvirlash usullari natijalari bilan birgalikda talqin qilinganda, ko‘krak bezi kasalliklarining benign va malign holatlarini farqlashda yordam berishi mumkin. Konsentratsiya odatda o‘sma yuklamasini aks ettiradi va vaqt o‘tishi bilan dinamikada kuzatilib, boshqaruv bo‘yicha qarorlarni shakllantirishda ma’lumot beradi.
Cheklovlar
CA 15-3 normal ko‘krak bezi epiteliyasi tomonidan ishlab chiqariladigan va ko‘plab ko‘krak bezi karsinomalarida ortiqcha ekspressiyalanadigan, yuqori molekulyar massali mukinoz glikoproteindir. Qon zardobidagi konsentratsiya ko‘krak bezining erta bosqichdagi saratonida taxminan 10% hollarda va metastatik kasallikda taxminan 70% hollarda oshgan bo‘ladi. Ushbu test erta ko‘krak bezi saratonini tashxislash uchun yetarli darajada sezgir yoki spetsifik emas, va natijalar klinik baholash hamda boshqa diagnostik protseduralar bilan korrelyatsiyada talqin qilinishi lozim. CA 15-3 ning ko‘tarilishi faqat ko‘krak bezi malignitetiga xos emas. Darajalarning oshishi boshqa o‘smalarda (masalan, kolorektal, o‘pka, tuxumdon, bachadon bo‘yni, endometriy), ko‘krak bezining benign kasalliklarida, gepatit va sirroz kabi surunkali jigar kasalliklarida hamda homiladorlik davrida kuzatilishi mumkin.
| Referens oraliq |
| ||||
|---|---|---|---|---|---|
| Ko'rsatmalar | Ongoing surveillance of breast cancer to inform treatment planning and adjustments, Serial evaluation of therapeutic effectiveness and recurrence detection in patients with an initially elevated CA 15-3 |
Natija og'ishlarining mumkin sabablari
Oshgan daraja
- autoimmune disease
- sarcoidosis
- tuberculosis
Pasaygan daraja
- biotin
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 1 mL (min 0.7 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Hayes DF, Zurawski VR Jr, Kufe DW. Comparison of Circulating CA 15-3 and Carcinoembryonic Antigen Levels in Patients With Breast Cancer. J Clin Oncol. 1986;4(10):1542-1550. PubMed 2428949.